Related Experiment Video
Updated: Jul 5, 2026
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
Therapeutic cancer drugs. 9-10 July 1998, London, UK
1Chiroscience Group plc, Cambridge Science Park, Milton Road, Cambridge, CB4 4WE, UK. BobJackson@Chiroscience.com
Abstract:
In line with the SMi objective of 'linking business with information', this meeting addressed a number of aspects of oncological drug development that must be grappled with by companies that are attempting to build a business in this area. Some of the recurring themes of many of the presentations were summarized by the Chairman, Dr Roy Drucker (Technomark, UK) in his closing remarks. Many of the innovative new anticancer drugs have their origins in start-up companies, but their clinical development is generally in the hands of multinational pharmaceutical companies. Such alliances, while often productive and mutually advantageous, present management challenges. There were concerns expressed that the innovation from biotechnology and pharmaceutical companies might not be matched at the regulatory end. The increasing individualization of treatment is likely to expand in the future through the use of functional genomics tools, that may increase response rates, but will do so at the cost of complicating the development and regulatory process, and will result in an increasingly fragmented market. Cancer medicine is increasingly politicized: there are issues of "who gets what" and "who pays for it". Patient support groups are increasingly expecting to contribute to these decisions. As treatment gets more expensive and complex, the gulf between treatment practices in rich and poor countries widens; nevertheless, many emerging economies are generating a prosperous middle class who will expect first-world standards of care, and present a market opportunity. Finally, pharmaceutical industry management still tend to treat oncology as a poor relation to its more lavishly funded cardiovascular and CNS programs, an attitude that is not entirely market-driven but reflects confusion about this complex and rapidly-changing area.
Insights
Developing innovative anticancer drugs presents challenges in business and regulation. Alliances between startups and large companies are key, but market fragmentation and access issues persist globally.
Area of Science:
- Oncology
- Pharmaceutical Business
- Drug Development
Background:
- Innovative anticancer drugs often originate in startups, with multinational pharmaceutical companies handling clinical development.
- Alliances between biotech startups and large pharma are common but pose management challenges.
- Concerns exist regarding the pace of regulatory innovation compared to advancements in biotechnology.
Purpose of the Study:
- To summarize key challenges and themes in oncological drug development and business strategy.
- To highlight the complexities of managing collaborations between innovative startups and established pharmaceutical firms.
- To discuss the evolving landscape of cancer medicine, including market fragmentation and global disparities.
Main Methods:
- The content is based on a summary of presentations from a meeting focused on oncological drug development.
- Key themes were identified and synthesized by the chairman in closing remarks.
- Discussions covered business, clinical development, regulatory aspects, and market dynamics.
Main Results:
- The increasing individualization of cancer treatment, driven by functional genomics, complicates development and fragments the market.
- Cancer medicine faces politicization regarding treatment access and cost, with growing patient group involvement.
- A widening gap in treatment standards exists between developed and developing countries, despite market opportunities in emerging economies.
- Oncology is sometimes perceived as a lower priority within pharmaceutical companies compared to other therapeutic areas.
Conclusions:
- Successful oncological drug development requires navigating complex alliances, regulatory hurdles, and market access issues.
- The future of cancer treatment involves personalized medicine, which necessitates addressing cost, access, and market segmentation.
- Strategic management and a clear understanding of the rapidly evolving oncology landscape are crucial for pharmaceutical companies.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers